Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Diabetes in Developing Countries
Published in: International Journal of Diabetes in Developing Countries 3/2017

01-09-2017 | Review Article

Genetic variation, biological structure, sources, and fundamental parts played by CXCL12 in pathophysiology of type 1 diabetes mellitus

Authors: Mojgan Noroozi Karimabad, Hossein Khoramdelazad, Gholamhossein Hassanshahi

Published in: International Journal of Diabetes in Developing Countries | Issue 3/2017

Login to get access

Abstract

Type I diabetes (TID) is defined as an autoimmune disease resulting from the destruction of insulin-producing beta-cells by autoreactive T cells. It is believed that TID resulted from the immune-mediated destruction of insulin-producing β-cells in pancreatic islets of Langerhans. Chemokines are small glycoproteins (weighing 8–10 kDa) that are attractive chemotactive factors for a wide variety of cell types, especially immune system cells and their target cells which express appropriate G protein receptors. It has been well established that chemokines as the main arms of the immune system play key roles in the regulation of immune responses which is evidenced to be important in the pathogenesis of the diseases. Several other environmental and genetic components of the immune systems also confirmed to influence the onset of immune-related diseases. The CXC chemokine CXCL12 is involved in the development of immune responses. Previous studies reported that the known genetic variation SDF1–3′A regulates the expression of CXCL12. Hence, the aim of this study was to address the latest findings regarding the relation between the serum concentrations and CXCL12 genetic variation, in SDF1–3′A in T1D.
Literature
1.
Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature. 2000;403(6766):216–20.CrossRefPubMed
2.
Arababadi MK, Nasiri Ahmadabadi B, Kennedy D. Current information on the immunologic status of occult hepatitis B infection. Transfusion. 2012;52(8):1819–26.CrossRefPubMed
3.
Al Ghamdi AA, Badr G, Hozzein WN, Allam A, Al-Waili NS, Al-Wadaan MA, et al. Oral supplementation of diabetic mice with propolis restores the proliferation capacity and chemotaxis of B and T lymphocytes towards CCL21 and CXCL12 by modulating the lipid profile, the pro-inflammatory cytokine levels and oxidative stress. BMC Immunol. 2015;16:54.CrossRefPubMedPubMedCentral
4.
Miyara M, Wing K, Sakaguchi S. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. J Allergy Clin Immunol. 2009;123(4):749–55. quiz 56-7CrossRefPubMed
5.
Jamali Z, Nazari M, Khoramdelazad H, Hakimizadeh E, Mahmoodi M, Karimabad MN, et al. Expression of CC chemokines CCL2, CCL5, and CCL11 is associated with duration of disease and complications in type-1 diabetes: a study on Iranian diabetic patients. Clin Lab. 2013;59(9-10):993–1001.PubMed
6.
Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev. 1994;15(4):516–42.CrossRefPubMed
7.
Obermannova B, Petruzelkova L, Sulakova T, Sumnik Z. HbA1c but not diabetes duration predicts increased arterial stiffness in adolescents with poorly controlled type 1 diabetes. Pediatr Diabetes 2016
8.
Pulikkal AA, Kolly A, Prasanna Kumar KM, Shivaprasad C. The seroprevalence of immunoglobulin A transglutaminase in type 1 diabetic patients of South Indian origin. Indian J Endocrinol Metab. 2016;20(2):233–7.CrossRefPubMedPubMedCentral
9.
Puff R, D’Orlando O, Heninger AK, Kuhn D, Krause S, Winkler C, et al. Compromised immune response in infants at risk for type 1 diabetes born by Caesarean Section. Clin Immunol (Orlando, Fla). 2015;160(2):282–5.CrossRef
10.
Siegel KR, Echouffo-Tcheugui JB, Ali MK, Mehta NK, Narayan KM, Chetty V. Societal correlates of diabetes prevalence: An analysis across 94 countries. Diabetes Res Clin Pract. 2012;96(1):76–83.CrossRefPubMed
11.
Green A, Patterson CC. Trends in the incidence of childhood-onset diabetes in Europe 1989-1998. Diabetologia. 2001;44(Suppl 3):B3–8.CrossRefPubMed
12.
Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med. 2001;345(14):1036–40.CrossRefPubMed
13.
Nathanson D, Nystrom T. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium. Mol Cell Endocrinol. 2009;297(1-2):112–26. Epub 2008/11/29CrossRefPubMed
14.
Bluestone JA, Tang Q, Sedwick CE. T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol. 2008;28(6):677–84.CrossRefPubMed
15.
Calderon TM, Eugenin EA, Lopez L, Kumar SS, Hesselgesser J, Raine CS, et al. A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol. 2006;177(1-2):27–39.CrossRefPubMed
16.
Pundziute-Lycka A, Dahlquist G, Nystrom L, Arnqvist H, Bjork E, Blohme G, et al. The incidence of Type I diabetes has not increased but shifted to a younger age at diagnosis in the 0-34 years group in Sweden 1983-1998. Diabetologia. 2002;45(6):783–91.CrossRefPubMed
17.
Cipolletta C, Ryan KE, Hanna EV, Trimble ER. Activation of peripheral blood CD14+ monocytes occurs in diabetes. Diabetes. 2005;54(9):2779–86.CrossRefPubMed
18.
Devaraj S, Cheung AT, Jialal I, Griffen SC, Nguyen D, Glaser N, et al. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes. 2007;56(11):2790–6.CrossRefPubMedPubMedCentral
19.
Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes. 2006;55(3):774–9.CrossRefPubMed
20.
21.
Hassanshahi G, Patel SS, Jafarzadeh AA, Dickson AJ. Expression of CXC chemokine IP-10/Mob-1 by primary hepatocytes following heat shock. Saudi Med J. 2007;28(4):514–8.PubMed
22.
Abousaidi H, Vazirinejad R, Arababadi MK, Rafatpanah H, Pourfathollah AA, Derakhshan R, et al. Lack of association between chemokine receptor 5 (CCR5) delta32 mutation and pathogenesis of asthma in Iranian patients. South Med J. 2011;104(6):422–5.CrossRefPubMed
23.
Hassanshahi G, Jafarzadeh A, James DA. Expression of stromal derived factor alpha (SDF-1 alpha) by primary hepatocytes following isolation and heat shock stimulation. Iran J Allergy, Asthma, Immunol. 2008;7(2):61–8.
24.
Karimabad NMHG, Arababadi MK, Shabani Z, Shamsizadeh A, Rafatpanah H, et al. Decreased Circulating Level in Parallel With Lack of Associated Genetic Variation in CXCL10 (IP-10) in Southeastern Post-Transfusion Occult HBV Infected Patients. Lab Med. 2011;42(7):13–6.CrossRef
25.
Radman M, Hassanshahi G, Vazirinejad R, Arababadi MK, Karimabad MN, Khorramdelazad H, et al. Serum Levels of the CC Chemokines CCL2, CCL5, and CCL11 in Food Allergic Children with Different Clinical Manifestations. Inflammation 2012
26.
Khandany BK, Hassanshahi G, Khorramdelazad H, Balali Z, Shamsizadeh A, Arababadi MK, et al. Evaluation of circulating concentrations of CXCL1 (Gro-alpha), CXCL10 (IP-10) and CXCL12 (SDF-1) in ALL patients prior and post bone marrow transplantation. Pathol Res Pract. 2012;208(10):615–9.CrossRefPubMed
27.
Derakhshan R, Arababadi MK, Ahmadi Z, Karimabad MN, Salehabadi VA, Abedinzadeh M, et al. Increased circulating levels of SDF-1 (CXCL12) in type 2 diabetic patients are correlated to disease state but are unrelated to polymorphism of the SDF-1beta gene in the Iranian population. Inflammation. 2012;35(3):900–4.CrossRefPubMed
28.
Hakimizadeh E, Shamsizadeh A, Nazari M, Arababadi MK, Rezaeian M, Vazirinejad R, et al. Increased circulating levels of CXC chemokines is correlated with duration and complications of the disease in type-1 diabetes: a study on Iranian diabetic patients. Clin Lab. 2013;59(5-6):531–7.PubMed
29.
Aminzadeh F, Ghorashi Z, Nabati S, Ghasemshirazi M, Arababadi MK, Shamsizadeh A, et al. Differential expression of CXC chemokines CXCL10 and CXCL12 in term and pre-term neonates and their mothers. American journal of reproductive immunology (New York, NY : 1989). 2012;68(4):338-44
30.
Daryani A, Hosseini AZ, Dalimi A. Immune responses against excreted/secreted antigens of Toxoplasma gondii tachyzoites in the murine model. Vet Parasitol. 2003;113(2):123–34.CrossRefPubMed
31.
Azin H, Vazirinejad R, Ahmadabadi BN, Khorramdelazad H, Zarandi ER, Arababadi MK, et al. The SDF-1 3’a genetic variation of the chemokine SDF-1alpha (CXCL12) in parallel with its increased circulating levels is associated with susceptibility to MS: a study on Iranian multiple sclerosis patients. J Mol Neurosci: MN. 2012;47(3):431–6.CrossRefPubMed
32.
Hassanshahi G, Arababadi MK, Khoramdelazad H, Yaghini N, Zarandi ER. Assessment of CXCL12 (SDF-1alpha) polymorphisms and its serum level in posttransfusion occult HBV-infected patients in Southeastern Iran. Arch Med Res. 2010;41(5):338–42.CrossRefPubMed
33.
Khabour OF, Abu-Haweleh LJ, Alzoubi KH. Distribution Of CCR-5Delta32, CCR2-64I, and SDF-1-3’A Alleles Among Jordanians. AIDS Res Hum Retrovir 2012.
34.
Arababadi MKMM, Sajadi SMA, Hassanshahi G, Ahmadababdi BN, Salehabadi VA. et a. nterleukin (IL)-10 gene polymorphisms is associated with type 2 diabetes with and without nephropathy: a study of patients from the South-East region of Iran. Inflammation. 2012:s10753–011-9381-x.
35.
Nishioji K, Okanoue T, Itoh Y, Narumi S, Sakamoto M, Nakamura H, et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol. 2001;123(2):271–9.CrossRefPubMedPubMedCentral
36.
Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A. 1994;91(6):2305–9.CrossRefPubMedPubMedCentral
37.
Gleichmann M, Gillen C, Czardybon M, Bosse F, Greiner-Petter R, Auer J, et al. Cloning and characterization of SDF-1gamma, a novel SDF-1 chemokine transcript with developmentally regulated expression in the nervous system. Eur J Neurosci. 2000;12(6):1857–66.CrossRefPubMed
38.
Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996;184(3):1101–9.CrossRefPubMed
39.
Guinamard R, Signoret N, Ishiai M, Marsh M, Kurosaki T, Ravetch JV. B cell antigen receptor engagement inhibits stromal cell-derived factor (SDF)-1alpha chemotaxis and promotes protein kinase C (PKC)-induced internalization of CXCR4. J Exp Med. 1999;189(9):1461–6.CrossRefPubMedPubMedCentral
40.
Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, et al. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics. 1995;28(3):495–500.CrossRefPubMed
41.
Holmes WD, Consler TG, Dallas WS, Rocque WJ, Willard DH. Solution studies of recombinant human stromal-cell-derived factor-1. Protein Expr Purif. 2001;21(3):367–77.CrossRefPubMed
42.
Fedyk ER, Jones D, Critchley HO, Phipps RP, Blieden TM, Springer TA. Expression of stromal-derived factor-1 is decreased by IL-1 and TNF and in dermal wound healing. J Immunol (Baltimore, Md : 1950). 2001;166(9):5749–54.CrossRef
43.
44.
Wuyts A, Haelens A, Proost P, Lenaerts JP, Conings R, Opdenakker G, et al. Identification of mouse granulocyte chemotactic protein-2 from fibroblasts and epithelial cells. Functional comparison with natural KC and macrophage inflammatory protein-2. J Immunol (Baltimore, Md : 1950). 1996;157(4):1736–43.
45.
Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998;393(6685):595–9.CrossRefPubMed
46.
Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382(6592):635–8.CrossRefPubMed
47.
Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998;393(6685):591–4.CrossRefPubMed
48.
Kipps S, Bahu T, Ong K, Ackland FM, Brown RS, Fox CT, et al. Current methods of transfer of young people with Type 1 diabetes to adult services. Diabet Med: J Br Diabetic Assoc. 2002;19(8):649–54.CrossRef
49.
Loetscher P, Gong JH, Dewald B, Baggiolini M, Clark-Lewis I. N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities. J Biol Chem. 1998;273(35):22279–83.CrossRefPubMed
50.
Terada R, Yamamoto K, Hakoda T, Shimada N, Okano N, Baba N, et al. Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-positive cells: implications for inflammatory liver diseases. Lab Investig; J Tech Meth Pathol. 2003;83(5):665-72.
51.
Mohl W, Lerch MM, Klotz M, Freidank H, Zeitz M. Infection of an intravenous port system with Metschnikowia pulcherrima Pitt et Miller. Mycoses. 1998;41(9-10):425–6.CrossRefPubMed
52.
Nagasawa T, Tachibana K, Kishimoto T. A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol. 1998;10(3):179–85.CrossRefPubMed
53.
Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17(8):2074–80.CrossRef
54.
Blades MC, Ingegnoli F, Wheller SK, Manzo A, Wahid S, Panayi GS, et al. Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice. Arthritis Rheum. 2002;46(3):824–36.CrossRefPubMed
55.
Balabanian K, Couderc J, Bouchet-Delbos L, Amara A, Berrebi D, Foussat A, et al. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J Immunol (Baltimore, Md : 1950). 2003;170(6):3392–400.CrossRef
56.
Dziembowska M, Tham TN, Lau P, Vitry S, Lazarini F, Dubois-Dalcq M. A role for CXCR4 signaling in survival and migration of neural and oligodendrocyte precursors. Glia. 2005;50(3):258–69.CrossRefPubMed
57.
Ambrosini E, Remoli ME, Giacomini E, Rosicarelli B, Serafini B, Lande R, et al. Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J Neuropathol Exp Neurol. 2005;64(8):706–15.CrossRefPubMed
58.
Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, Ransohoff RM, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain J Neurol. 2006;129(Pt 1):200–11.
59.
Meiron M, Zohar Y, Anunu R, Wildbaum G, Karin N. CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J Exp Med. 2008;205(11):2643–55.CrossRefPubMedPubMedCentral
60.
Kawasaki E, Ide A, Abiru N, Kobayashi M, Fukushima T, Kuwahara H, et al. Stromal cell-derived factor-1 chemokine gene variant in patients with type 1 diabetes and autoimmune thyroid disease. Ann N Y Acad Sci. 2004;1037:79–83.CrossRefPubMed
61.
Secchiero P, Zella D, Curreli S, Mirandola P, Capitani S, Gallo RC, et al. Engagement of CD28 modulates CXC chemokine receptor 4 surface expression in both resting and CD3-stimulated CD4+ T cells. J Immunol (Baltimore, Md : 1950). 2000;164(8):4018–24.CrossRef
62.
Terasaki M, Sugita Y, Arakawa F, Okada Y, Ohshima K, Shigemori M. CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target. Brain tumor pathology. 2011;28(2):89–97.CrossRefPubMed
63.
Poggi A, Catellani S, Fenoglio D, Borsellino G, Battistini L, Zocchi MR. Adhesion molecules and kinases involved in gammadelta T cells migratory pathways: implications for viral and autoimmune diseases. Curr Med Chem. 2007;14(30):3166–70.CrossRefPubMed
64.
Poznansky MC, Olszak IT, Foxall R, Evans RH, Luster AD, Scadden DT. Active movement of T cells away from a chemokine. Nat Med. 2000;6(5):543–8.CrossRefPubMed
65.
Sharp CD, Huang M, Glawe J, Patrick DR, Pardue S, Barlow SC, et al. Stromal cell-derived factor-1/CXCL12 stimulates chemorepulsion of NOD/LtJ T-cell adhesion to islet microvascular endothelium. Diabetes. 2008;57(1):102–12.CrossRefPubMed
66.
Papeta N, Chen T, Vianello F, Gererty L, Malik A, Mok YT, et al. Long-term survival of transplanted allogeneic cells engineered to express a T cell chemorepellent. Transplantation. 2007;83(2):174–83.CrossRefPubMed
67.
Nti BK, Markman JL, Bertera S, Styche AJ, Lakomy RJ, Subbotin VM, et al. Treg cells in pancreatic lymph nodes: the possible role in diabetogenesis and beta cell regeneration in a T1D model. Cell Mol Immunol. 2012;9(6):455–63.CrossRefPubMedPubMedCentral
68.
Vidakovic M, Grdovic N, Dinic S, Mihailovic M, Uskokovic A, Arambasic JJ. The Importance of the CXCL12/CXCR4 Axis in Therapeutic Approaches to Diabetes Mellitus Attenuation. Front Immunol. 2015;6:403.PubMedPubMedCentral
69.
Chen T, Yuan J, Duncanson S, Hibert ML, Kodish BC, Mylavaganam G, et al. Alginate encapsulant incorporating CXCL12 supports long-term allo- and xenoislet transplantation without systemic immune suppression. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2015;15(3):618–27.CrossRef
70.
Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011;71(16):5522–34.CrossRefPubMedPubMedCentral
71.
Matin K, Salam MA, Akhter J, Hanada N, Senpuku H. Role of stromal-cell derived factor-1 in the development of autoimmune diseases in non-obese diabetic mice. Immunology. 2002;107(2):222–32.CrossRefPubMedPubMedCentral
72.
Zhao Y, Guo C, Hwang D, Lin B, Dingeldein M, Mihailescu D, et al. Selective destruction of mouse islet beta cells by human T lymphocytes in a newly-established humanized type 1 diabetic model. Biochem Biophys Res Commun. 2010;399(4):629–36.CrossRefPubMed
73.
Aboumrad E, Madec AM, Thivolet C. The CXCR4/CXCL12 (SDF-1) signalling pathway protects non-obese diabetic mouse from autoimmune diabetes. Clin Exp Immunol. 2007;148(3):432–9.CrossRefPubMedPubMedCentral
74.
Noh YH, Yim YS, Kim DH, Lee MW, Kim DS, Kim HR, et al. Correlation between chemokines released from umbilical cord blood-derived mesenchymal stem cells and engraftment of hematopoietic stem cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Pediatr Hematol Oncol. 2011;28(8):682–90.CrossRefPubMed
75.
Ferraro F, Lymperi S, Mendez-Ferrer S, Saez B, Spencer JA, Yeap BY, et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med. 2011;3(104):104ra1.CrossRef
76.
Jie W, Wang X, Zhang Y, Guo J, Kuang D, Zhu P, et al. SDF-1alpha/CXCR4 axis is involved in glucose-potentiated proliferation and chemotaxis in rat vascular smooth muscle cells. Int J Exp Pathol. 2010;91(5):436–44.CrossRefPubMedPubMedCentral
77.
Leng Q, Nie Y, Zou Y, Chen J. Elevated CXCL12 expression in the bone marrow of NOD mice is associated with altered T cell and stem cell trafficking and diabetes development. BMC Immunol. 2008;9:51.CrossRefPubMedPubMedCentral
78.
Al Ghamdi AA, Badr G, Hozzein WN, Allam A, Al-Waili NS, Al-Wadaan MA, et al. Oral supplementation of diabetic mice with propolis restores the proliferation. D - 100966980. (- 1471-2172 (Electronic)):- 54.
79.
Glawe JD, Mijalis EM, Davis WC, Barlow SC, Gungor N, McVie R, et al. SDF-1-CXCR4 differentially regulates autoimmune diabetogenic T cell adhesion through ROBO1-SLIT2 interactions in mice. Diabetologia. 2013;56(10):2222–30.CrossRefPubMed
80.
Albiero M, Poncina N, Ciciliot S, Cappellari R, Menegazzo L, Ferraro F, et al. Bone Marrow Macrophages Contribute to Diabetic Stem Cell Mobilopathy by Producing Oncostatin M. Diabetes. 2015;64(8):2957–68.CrossRefPubMed
81.
Dubois-Laforgue D, Hendel H, Caillat-Zucman S, Zagury JF, Winkler C, Boitard C, et al. A common stromal cell-derived factor-1 chemokine gene variant is associated with the early onset of type 1 diabetes. Diabetes. 2001;50(5):1211–3.CrossRefPubMed
82.
Park Y, Tait BD, Kawasaki E, Rowley M, Mackay IR. Closer association of IA-2 humoral autoreactivity with HLA DR3/4 than DQB1*0201/*0302 in Korean T1D patients. Ann N Y Acad Sci. 2004;1037:104–9.CrossRefPubMed
83.
Razmkhah M, Doroudchi M, Ghayumi SM, Erfani N, Ghaderi A. Stromal cell-derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer. Lung Cancer (Amsterdam, Netherlands). 2005;49(3):311–5.CrossRef
84.
Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes. 1994;43(5):667–75.CrossRefPubMed
85.
Nanki T, Lipsky PE. Cutting edge: stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation. J Immunol (Baltimore, Md: 1950). 2000;164(10):5010–4.CrossRef
86.
Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science (New York, NY). 1998;279(5349):389-93.
87.
Arya SK, Ginsberg CC, Davis-Warren A, D’Costa J. In vitro phenotype of SDF1 gene mutant that delays the onset of human immunodeficiency virus disease in vivo. J Hum Virol. 1999;2(3):133–8.PubMed
88.
Mein CA, Esposito L, Dunn MG, Johnson GC, Timms AE, Goy JV, et al. A search for type 1 diabetes susceptibility genes in families from the United Kingdom. Nat Genet. 1998;19(3):297–300.CrossRefPubMed
89.
Reed P, Cucca F, Jenkins S, Merriman M, Wilson A, McKinney P, et al. Evidence for a type 1 diabetes susceptibility locus (IDDM10) on human chromosome 10p11-q11. Hum Mol Genet. 1997;6(7):1011–6.CrossRefPubMed
90.
Khorramdelazad H, Bagheri V, Hassanshahi G, Zeinali M, Vakilian A. New insights into the role of stromal cell-derived factor 1 (SDF-1/CXCL12) in the pathophysiology of multiple sclerosis. J Neuroimmunol. 2016;290:70–5.CrossRefPubMed
91.
Karimabad MN, Hassanshahi G. Significance of CXCL12 in type 2 diabetes mellitus and its associated complications. Inflammation. 2015;38(2):710–7.CrossRefPubMed
92.
Ide A, Kawasaki E, Abiru N, Sun F, Fukushima T, Takahashi R, et al. Stromal-cell derived factor-1 chemokine gene variant is associated with type 1 diabetes age at onset in Japanese population. Hum Immunol. 2003;64(10):973–8.CrossRefPubMed
93.
Shigihara T, Shimada A, Yamada S, Maruyama T, Hirose H, Saruta T. Stromal cell-derived factor-1 chemokine gene polymorphism is not associated with onset age of Japanese type 1 diabetes. Ann N Y Acad Sci. 2003;1005:328–31.CrossRefPubMed
Metadata
Title
Genetic variation, biological structure, sources, and fundamental parts played by CXCL12 in pathophysiology of type 1 diabetes mellitus
Authors
Mojgan Noroozi Karimabad
Hossein Khoramdelazad
Gholamhossein Hassanshahi
Publication date
01-09-2017
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 3/2017
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-016-0534-1

Other articles of this Issue 3/2017

International Journal of Diabetes in Developing Countries 3/2017 Go to the issue

Original Article

The effect of aerobic exercise training on β-cell function and circulating levels of adipsin in community of obese women with type 2 diabetes mellitus

Original Article

Incidence of type-2 diabetes among industrial Workers in Kerala, India

Letter to the Editor

Influx of recombinant insulin and its analogues for management of diabetes in India

Original Article

The predictive value of diabetes-related antibodies in children with type 1 diabetes mellitus and their siblings

Case Report

Proliferative glomerulonephritis with monoclonal IgG deposits in a patient with diabetes mellitus

Original Article

Dual X-ray absorptiometry body composition and its associated factors in children and adolescence with type 1 diabetes mellitus in South of Iran, a case-control study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits